Open-label, Randomised, Phase 2 Study in Patients With Advanced Solid Tumours to Determine Effect of Food Upon Pharmacokinetics of a Single Oral Dose of Cediranib (AZD2171, Recentin), Followed by an Assessment of the Safety and Tolerability of Fixed and Individualised Daily Dosing

Trial Profile

Open-label, Randomised, Phase 2 Study in Patients With Advanced Solid Tumours to Determine Effect of Food Upon Pharmacokinetics of a Single Oral Dose of Cediranib (AZD2171, Recentin), Followed by an Assessment of the Safety and Tolerability of Fixed and Individualised Daily Dosing

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2012

At a glance

  • Drugs Cediranib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Sep 2008 Planned end date changed from 1 Mar 2009 to 1 Sep 2008, as reported by Clinicaltrials.gov.
    • 12 Sep 2008 Status changed from active, no longer recruiting to completed, as repotred by ClinicalTrials.gov.
    • 05 Nov 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top